Other · developed by Prime Medicine
PM647a is being studied in participants with alpha-1 antitrypsin deficiency caused by a homozygous Pi*Z allele (Pi*ZZ genotype), including those with lung or liver involvement.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07887347 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency | Not yet recruiting | PRME |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AATDAlpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency-associated Lung Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRME page.
See PRME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRME catalysts and pipeline →